Abstract：The Myriad Case concerns the dispute on the Patentability of Human Genome between Association for Molecular Pathology and Myriad Genetics, Inc.The decision of the Supreme Court held, “A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring.” The Myriad Case is a milestone of patent protection history in the area of biotechnology.
苟大凯. 人类基因的可专利性之争——Myriad 案评析[J]. 中国科技论坛, 2014(8): 127-131.
Gou Dakai. Dispute on the Patentability of Human Genome:a Case Study on the Myriad Case. , 2014(8): 127-131.
[1]王岩.知识产权资产——从法律到经济的枢纽概念[J].知识产权, 2013, (7). [2]Linda J Demaine, Aaron Xavier Fellmeth.Reinventing the Double Helix:A Novel and Nonobvious Reconceptualization of the Biotechnology Patent[J].Stan.L.Rev., 2002, (55):303. [3]张炳生.论现代生物技术的可专利性主题[J].法学, 2008, (7). [4]赵雷.美国2011年专利法第一案Myriad案评析——人类基因可专利性的再思考[J].知识产权, 2012, (6). [5]Gregory Dolin.Exclusivity without Patents:The New Frontier of FDA Regulation for Genetic Materials[J].IOWA law review, 2013, (98):1402-1403. [6]Dan L Burk, Mark A Lemley.Policy Levers in Patent Law[J].VA.L.REV., 2003, (89):1575, 1625-1626.
2014, 
